Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLAREMI: Cladribine Effects on Remyelination in MS
NCT05902429Phase 4Active, not recruiting
- Sponsor
- Pontifical Catholic University of Rio Grande do Sul
- Start
- Apr 2021
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cladribine in relapsing-remitting multiple sclerosis (RRMS), sponsored by Pontifical Catholic University of Rio Grande do Sul. Primary endpoint: Proportion of remyelinated lesions in q-Space myelin map at 36 months. Started Apr 2021; status: active, not recruiting.
02
Drugs
cladribine
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT05902429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05902429.